Hill Creek Partners
VC Fund
Hill Creek Partners is an investment firm.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hill Creek Partners invests in
Stages Hill Creek Partners invests in
Countries Hill Creek Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James A. Ratigan Sr
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 2 (67%)
- Pet 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series A 2 (67%)
- Series B 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
James A. Ratigan Sr
Managing Member
|
Managing Member | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $18M / Series B / Mar 15, 2025 | |
Gallant Therapeutics
|
Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals. | $15M / Series A / Jan 08, 2024 | |
|
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $15M / Series A / Jan 08, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hill Creek Partners invest in?
Hill Creek Partners invests primarily in Biotechnology, Pet and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hill Creek Partners?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hill Creek Partners?
The team at Hill Creek Partners includes James A. Ratigan Sr (Managing Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
